Walk With Me: a Mobile Application to Improve Walking in Persons With MS

2019-10-31 14:29:34 | BioPortfolio


During 10 weeks the subjects will use a mobile application (Walk with Me). The aim of this study is to investigate the usability of the mobile application, as well as investigating if the mobile application effects walking.

Study Design


Multiple Sclerosis


Walk with Me app


Hasselt University




Hasselt University

Results (where available)

View Results


Published on BioPortfolio: 2019-10-31T14:29:34-0400

Clinical Trials [1939 Associated Clinical Trials listed on BioPortfolio]

Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis

The purpose of this study is to investigate whether a wearable robotic exoskeleton can help people with multiple sclerosis (MS) to walk again.

Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

The primary objective is to assess the activity of nerispirdine in improving the ability to walk, in patients with multiple sclerosis (MS). Secondary objectives: - To assess oth...

Auditory Function in Patients With and Without Multiple Sclerosis

We propose to evaluate auditory function and neuropsychologic function in 150 Multiple Sclerosis (MS) patients and in 150 patients who do not have MS. Experimental subjects will be recrui...

Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop

People with Multiple Sclerosis (pwMS) often experience 'foot-drop' which means that the foot is not adequately lifted during the so-called swing phase (foot is off the ground) during walki...

Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis

Regular physical activity improves aspects such as physical fitness, fatigue, quality of life, gait and also reduces the rate of progression of disability in individuals with Multiple Scle...

PubMed Articles [6278 Associated PubMed Articles listed on BioPortfolio]

Walking endurance in multiple sclerosis: Meta-analysis of six-minute walk test performance.

The 6-minute walk (6 MW) is the most commonly applied measure of endurance walking capacity in persons with multiple sclerosis (MS); however, we are not aware of a quantitative synthesis of 6 MW p...

Is the walk ratio a window to the cerebellum in multiple sclerosis? A structural MRI study.

Existing research studies have demonstrated a relationship between MRI neuroimaging measures and walking speed in people with multiple sclerosis (PwMS). However, to date there are no data as to the br...

Association between suicide and multiple sclerosis: An updated meta-analysis.

Whether multiple sclerosis is associated with a higher rate of suicide remains controversial. Therefore, we aimed to evaluate the risk of suicide in multiple sclerosis patients based on meta-analysis ...

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS.

Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries.

Risk of relapses during pregnancy among multiple sclerosis patients.

Relapse rate in women with Multiple Sclerosis (MS) is reduced during pregnancy especially in the third trimester according to the previous studies.

Medical and Biotech [MESH] Definitions

A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)

A non-glycosylated form of interferon beta-1 that has a serine at position 17. It is used in the treatment of both RELAPSING-REMITTING MULTIPLE SCLEROSIS and CHRONIC PROGRESSIVE MULTIPLE SCLEROSIS.

An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)

A measure of endurance tests that show how far and fast an individual can walk without stopping within a certain period of time.

The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

More From BioPortfolio on "Walk With Me: a Mobile Application to Improve Walking in Persons With MS"

Quick Search

Searches Linking to this Trial